Bevacizumab Alone Effective for Recurrent Glioblastoma

Share this content:

the Cancer Therapy Advisor take:

Single-agent bevacizumab is an effective and safe treatment for patients with recurrent glioblastoma, according to a recent study published in Medical Oncology.

Researchers led by Ilhan Hacibekiroglu of Trakya University in Turkey observed 22 patients with glioblastoma and two patients with World Health Organization III glioma who had been previously treated with temozolomide with radiotherapy and received 10mg/kg bevacizumab intravenously every two weeks until disease progression.

The researchers found that the performance status of 17 patients (70.8 percent) was improved with the bevacizumab regimen. Upon univariate analysis, performance status following bevacizumab therapy was found to be a significant predictor of both progression-free survival (PFS) and overall survival (OS).

In addition, overall response rate was 20.8 percent, with median OS at 6.4 months. Six-month PFS was 37.5 percent and median PFS was 4.1 months.

MRI of glioblastoma multiforme / Science Source
Single-agent bevacizumab is an effective and safe treatment for patients with recurrent glioblastoma.
The aim of this study was to evaluate the efficiency and safety of single-agent bevacizumab therapy for recurrent glioblastoma multiforme (GBM). The data suggest that improvement in performance status (IPS) following bevacizumab therapy was a significant predictor of both PFS and OS.
READ FULL ARTICLE From Mdlinx

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs